Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000598833 | SCV000709890 | pathogenic | not provided | 2018-08-29 | criteria provided, single submitter | clinical testing | The R4526X variant has been reported previously in association with Usher syndrome (Nakanishi et al., 2011). This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The variant is not observed in large population cohorts (Lek et al., 2016). In summary, we consider this variant to be pathogenic. |
Labcorp Genetics |
RCV000598833 | SCV001222765 | pathogenic | not provided | 2023-10-28 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg4526*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with USH2A-related conditions (PMID: 21593743, 28157192). ClinVar contains an entry for this variant (Variation ID: 438014). For these reasons, this variant has been classified as Pathogenic. |
Blueprint Genetics | RCV001074297 | SCV001239870 | pathogenic | Retinal dystrophy | 2019-06-18 | criteria provided, single submitter | clinical testing | |
Ophthalmic Genetics Group, |
RCV000504721 | SCV004030333 | pathogenic | Retinitis pigmentosa | 2023-07-24 | criteria provided, single submitter | research | Clinical significance based on ACMG v2.0 |
Genome- |
RCV000670712 | SCV004183153 | pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000670712 | SCV004200738 | pathogenic | Retinitis pigmentosa 39 | 2024-02-29 | criteria provided, single submitter | clinical testing | |
Institute of Medical Genetics and Applied Genomics, |
RCV000670712 | SCV005374598 | pathogenic | Retinitis pigmentosa 39 | 2024-10-15 | criteria provided, single submitter | clinical testing | |
NIHR Bioresource Rare Diseases, |
RCV000504721 | SCV000598789 | pathogenic | Retinitis pigmentosa | 2015-01-01 | no assertion criteria provided | research | |
Counsyl | RCV000670712 | SCV000795603 | pathogenic | Retinitis pigmentosa 39 | 2017-11-10 | no assertion criteria provided | clinical testing | |
Department of Clinical Genetics, |
RCV000504721 | SCV000926722 | pathogenic | Retinitis pigmentosa | 2018-04-01 | no assertion criteria provided | research | |
Natera, |
RCV001829437 | SCV002088252 | pathogenic | Usher syndrome type 2A | 2021-07-08 | no assertion criteria provided | clinical testing |